| |
HIV & COVID-19
|
| |
| |
There have been a handful of reports both anecdotal and some data from Spain, NY, SF, Geneva and China suggesting there does not appear to be a higher risk or HIV+ to get COVID-19 nor do they appear from these preliminary reports that HIV+ do worse once they get the virus. These reports are all preliminary & hodgepodge so we do not know yet but more data is being collected from 3 databases that I know of. Here are several of these reports from Spain, China, NY (no outcomes) & Geneva. Jules Levin, NATAP
COVID-19 in patients with HIV: clinical case series - (04/21/20)
On March 9, 2020, 2 weeks into the COVID-19 outbreak in Spain, 543 consecutive patients with SARS-CoV-2 infection had been admitted to hospital at Hospital Clínic Barcelona, Barcelona, Spain. We admitted 62 (12%) into intensive care units and we discharged 208 (38%) with supervised outpatient care. Of all patients, five (0·92%; 95% 0·39–2·14) were HIV positive (table), of whom three were male and two were transgender, and four identified as men who have sex with men (MSM). Two patients had comorbid conditions. Two patients were sex workers. Four were virologically suppressed: two with protease-inhibitor (darunavir-boosted cobicistat) and two with integrase-inhibitor (dolutegravir)-based antiretroviral therapy (ART). CD4 counts were above 400 cells per μL in all patients apart from patient 5, who was ART naive and a very advanced late presenter. Two patients had upper-respiratory tract infections, and three had viral pneumonia, including two requiring admission to the intensive care unit with invasive (patient 2) and non-invasive (patient 5) mechanical ventilation.....None of these five patients has died, although we admitted two to intensive care, where one remains.
WHO Report: HIV+ COVID Responses - (04/16/20)
HIV+ & COVID - response to this virus by HIV+ in China - (04/14/20)
Clinical Characteristics of Covid-19 in New York City - (04/23/20)
J&J statement: Lack of evidence to support use of darunavir-based treatments for SARS-CoV-2: - (04/20/20)
Atazanavir In Vitro vs COVID - A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19 - (04/20/20)
Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study - (04/21/20)
HIV/Infectious Disease Providers Launch CURE HIV-COVID Registry - (04/17/20)
COVID-19 in Patients With HIV - new study, database - https://clinicaltrials.gov/ct2/show/NCT04333953
COVID-19: Special Considerations for People Living with HIV - (04/24/20)
TDF/FTC/TAF COVID Inhibitors - (04/17/20)
|
|
| |
| |
|
|
|
